Mechanism of Arginine in Growth Hormone Stimulation Testing
Arginine stimulates growth hormone release primarily by suppressing hypothalamic somatostatin secretion, the endogenous inhibitor of GH, rather than by directly stimulating the pituitary gland. 1, 2
Primary Mechanism of Action
- Arginine works by reducing hypothalamic somatostatin tone, which normally inhibits GH release from the pituitary 1
- This mechanism has been confirmed through in vivo studies showing that arginine has no direct effect on pituitary somatotroph cells when tested in vitro 2
- The suppression of somatostatin allows endogenous GHRH to more effectively stimulate the pituitary, resulting in GH release 2, 3
Clinical Evidence Supporting the Mechanism
When arginine is combined with GHRH, the GH response is significantly greater than either agent alone, demonstrating that arginine's effect is mediated through removing somatostatin inhibition rather than direct pituitary stimulation 1:
- The GHRH-arginine test achieves 95% sensitivity and 91% specificity at a GH cutoff of 4.1 μg/L, comparable to the insulin tolerance test (ITT) 1
- Studies show arginine combined with GHRH produces higher GH levels (mean peak 72.7 μg/L) than GHRH alone (44.9 μg/L) or arginine alone (23.3 μg/L) 2
- This synergistic effect confirms that arginine removes inhibitory tone, allowing GHRH to work more effectively 2, 3
Alternative Mechanisms (Less Supported)
- Nitric oxide (NO) production from arginine does NOT appear to mediate GH release 4
- Studies using NOS inhibitors (L-NMMA) showed no change in arginine-stimulated GH secretion, and plasma cGMP levels remained unchanged 4
- While arginine can induce some endogenous GHRH release, this is a secondary mechanism compared to somatostatin suppression 5
Clinical Application and Test Performance
The FDA-approved indication for intravenous arginine (R-Gene 10) is as a pituitary stimulant for GH release, with expected peak responses of 10-30 ng/mL in normal subjects versus 0-10 ng/mL in pituitary-deficient patients 6:
- The test has a 32% false-positive rate and 27% false-negative rate when used alone 6
- Arginine alone performs much more poorly than the GHRH-arginine combination or ITT for diagnosing GHD 1
- The Endocrine Society guidelines recommend GHRH-arginine testing over arginine alone due to superior diagnostic accuracy 1
Important Clinical Caveats
Several factors can blunt the GH response to arginine stimulation 1, 7, 8:
- Obesity significantly reduces GH response, requiring BMI-adjusted cutoff values 1, 7, 8
- Higher BMI correlates with lower peak GH levels during arginine testing 8
- Younger children and those with higher BMI SDS show lower GH peaks 9
- The test has low reproducibility with only 56.5% concordance between first and second tests 9
Timing and Dosing Considerations
- Standard dosing is 30 grams of arginine infused over 30 minutes 2, 3
- Peak GH response typically occurs at 60-90 minutes after arginine administration 1, 10
- When combined with GHRH, the peak response is delayed compared to arginine alone (90 minutes vs 60 minutes) 10
- Blood sampling should continue for at least 120 minutes to capture the full GH response 1
Limitations in Specific Populations
The GHRH-arginine test can give falsely normal results in hypothalamic GHD 1:
- Patients with hypothalamic damage (e.g., from cranial irradiation within 10 years) may show normal responses because GHRH directly stimulates the intact pituitary 1
- In these cases, the ITT or glucagon stimulation test is preferred 1
- This limitation does not apply to arginine alone, which relies on endogenous GHRH release 1